drug
pasireotide
Marketedupdated 3mo agoby Recordati Corp
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying pasireotide
- phase2A Study of Pasireotide in People With Prolactinoma
- phase1Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule
- phase2Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
- phase2Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
- phase1A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310
- —Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
- phase4Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 14, 2026
123 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Dec 14, 2026compositionUS 7473761123d
- Dec 14, 2026compositionUS 7473761123d
- Dec 14, 2026compositionUS 7473761123d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that